BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications March 31, 2023
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers March 31, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01; DisTinGuish Trial of DKN-01 + tislelizumab & chemo to continue as a clinical collaboration March 31, 2023
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab) March 31, 2023
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte’s Oncology Pipeline March 15, 2023
Volastra Therapeutics in-licenses Clinical Stage KIF18A Inhibitor And Secures $60 Million in Series A Funding To Further Advance Cancer-Focused Pipeline March 15, 2023
Tachyon Receives Funding from CIRM for a Ph 1 Study of TACH101 in Patients with Advanced Solid Tumors March 15, 2023
Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments March 15, 2023
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate February 28, 2023
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates February 28, 2023
Kinnate Biopharma Acquires Ownership Stake from Kinnjiu Biopharma; Initiates Ph 1 Trial for Exarafenib (KIN-2787) in China February 28, 2023
Fusion Pharmaceuticals To Acquire Ph 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting metastatic CRPC February 22, 2023
Cullinan Oncology enters into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in the U.S. February 22, 2023
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors February 22, 2023
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination February 22, 2023
Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Ph 1b/2 Clinical Trial to the U.S. February 22, 2023
Akamis Bio, Parker Institute for Cancer Immunotherapy and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer February 22, 2023
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy February 22, 2023
Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA February 22, 2023
Nectin Therapeutics and Merck to test Anti-PVR Antibody NTX1088 + KEYTRUDA® in Patients with Locally Advanced and Metastatic Solid Tumors February 22, 2023
Actinium Signs Cooperative Research and Development Agreement with NCI to Further Enhance Clinical & Non-clinical Development of Actimab-A for the Treatment of AML and Other Hematologic Malignancies February 22, 2023
Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer February 22, 2023
